A citation-based method for searching scientific literature

Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan, Shu-Chen Lu, Robert J M Kurzeja, Glenn Sivits, Joanne Lin, Qing Chen, Zhulun Wang, Stephen A Thibault, Christina M Abbott, Tina Meng, Brandon Clavette, Christopher M Murawsky, Ian N Foltz, James B Rottman, Clarence Hale, Murielle M Véniant, David J Lloyd. Sci Transl Med 2018
Times Cited: 90







List of co-cited articles
1226 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
332
76

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
81
66

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
639
56

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
326
56

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
195
53


The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
161
34

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
86
34

A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Pia K Nørregaard, Maria A Deryabina, Pernille Tofteng Shelton, Jacob U Fog, Jens R Daugaard, Per-Olof Eriksson, Lone F Larsen, Lene Jessen. Diabetes Obes Metab 2018
56
51

Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
99
31

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
353
31

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition.
Kentaro Kaneko, Yukiko Fu, Hsiao-Yun Lin, Elizabeth L Cordonier, Qianxing Mo, Yong Gao, Ting Yao, Jacqueline Naylor, Victor Howard, Kenji Saito,[...]. J Clin Invest 2019
44
61



Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
830
25

Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions.
Daniela Nasteska, Norio Harada, Kazuyo Suzuki, Shunsuke Yamane, Akihiro Hamasaki, Erina Joo, Kanako Iwasaki, Kimitaka Shibue, Takanari Harada, Nobuya Inagaki. Diabetes 2014
119
25

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
24

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism.
Elizabeth A Killion, Michelle Chen, James R Falsey, Glenn Sivits, Todd Hager, Larissa Atangan, Joan Helmering, Jae Lee, Hongyan Li, Bin Wu,[...]. Nat Commun 2020
34
64

Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice.
Erina Joo, Norio Harada, Shunsuke Yamane, Toru Fukushima, Daisuke Taura, Kanako Iwasaki, Akiko Sankoda, Kimitaka Shibue, Takanari Harada, Kazuyo Suzuki,[...]. Diabetes 2017
50
42

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
Meena Asmar, Ali Asmar, Lene Simonsen, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Bolette Hartmann, Flemming Dela, Jens Juul Holst, Jens Bülow. Diabetes 2017
64
32

Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
732
21

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
73
26

Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice.
Michael O Boylan, Patricia A Glazebrook, Milos Tatalovic, M Michael Wolfe. Am J Physiol Endocrinol Metab 2015
37
48

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
147
20

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
203
20

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Natasha C Bergmann, Asger Lund, Lærke S Gasbjerg, Emma C E Meessen, Maria M Andersen, Sigrid Bergmann, Bolette Hartmann, Jens J Holst, Lene Jessen, Mikkel B Christensen,[...]. Diabetologia 2019
51
35

GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis.
Su-Jin Kim, Cuilan Nian, Subashini Karunakaran, Susanne M Clee, Carlos M Isales, Christopher H S McIntosh. PLoS One 2012
97
18

A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.
Sameer Mohammad, Rajesh T Patel, Joanne Bruno, Muhammad Siyab Panhwar, Jennifer Wen, Timothy E McGraw. Mol Cell Biol 2014
54
31

TCF1 links GIPR signaling to the control of beta cell function and survival.
Jonathan E Campbell, John R Ussher, Erin E Mulvihill, Jelena Kolic, Laurie L Baggio, Xiemen Cao, Yu Liu, Benjamin J Lamont, Tsukasa Morii, Catherine J Streutker,[...]. Nat Med 2016
77
22


Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A Killion, Shu-Chen Lu, Madeline Fort, Yuichiro Yamada, Murielle M Véniant, David J Lloyd. Endocr Rev 2020
28
60

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Jens Juul Holst, Mette Marie Rosenkilde. J Clin Endocrinol Metab 2020
44
38

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
Paula L McClean, Nigel Irwin, Roslyn S Cassidy, Jens J Holst, Victor A Gault, Peter R Flatt. Am J Physiol Endocrinol Metab 2007
185
17

Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans.
Meena Asmar, Lene Simonsen, Sten Madsbad, Bente Stallknecht, Jens Juul Holst, Jens Bülow. Diabetes 2010
95
17

Pharmacological antagonism of the incretin system protects against diet-induced obesity.
Berit Svendsen, Megan E Capozzi, Jingjing Nui, Sarah A Hannou, Brian Finan, Jacqueline Naylor, Peter Ravn, David A D'Alessio, Jonathan E Campbell. Mol Metab 2020
23
69

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
A H Sparre-Ulrich, L S Hansen, B Svendsen, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
57
26

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
430
16

Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
Peter Ravn, Chaithanya Madhurantakam, Susan Kunze, Evelyn Matthews, Claire Priest, Siobhan O'Brien, Andie Collinson, Monika Papworth, Maria Fritsch-Fredin, Lutz Jermutus,[...]. J Biol Chem 2013
60
25

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.
K Miyawaki, Y Yamada, H Yano, H Niwa, N Ban, Y Ihara, A Kubota, S Fujimoto, M Kajikawa, A Kuroe,[...]. Proc Natl Acad Sci U S A 1999
357
16

Functional GIP receptors are present on adipocytes.
R G Yip, M O Boylan, T J Kieffer, M M Wolfe. Endocrinology 1998
176
16

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.
Lærke S Gasbjerg, Mikkel B Christensen, Bolette Hartmann, Amalie R Lanng, Alexander H Sparre-Ulrich, Maria B N Gabe, Flemming Dela, Tina Vilsbøll, Jens J Holst, Mette M Rosenkilde,[...]. Diabetologia 2018
52
28

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
404
16

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
47
31

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
386
15

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
273
15

Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors.
Maria Buur Nordskov Gabe, Alexander Hovard Sparre-Ulrich, Mie Fabricius Pedersen, Lærke Smidt Gasbjerg, Asuka Inoue, Hans Bräuner-Osborne, Bolette Hartmann, Mette Marie Rosenkilde. Biochem Pharmacol 2018
48
29

N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
L S Hansen, A H Sparre-Ulrich, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
56
25

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.
Tanya Hansotia, Adriano Maida, Grace Flock, Yuichiro Yamada, Katsushi Tsukiyama, Yutaka Seino, Daniel J Drucker. J Clin Invest 2007
210
15


Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Francis S Willard, Jonathan D Douros, Maria Bn Gabe, Aaron D Showalter, David B Wainscott, Todd M Suter, Megan E Capozzi, Wijnand Jc van der Velden, Cynthia Stutsman, Guemalli R Cardona,[...]. JCI Insight 2020
65
21


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.